Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28957165 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL10029115 | 0.80 | — | — | |
| SCHEMBL6912305 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL380063 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL283370 | 0.79 | — | — | |
| SCHEMBL28287867 | 0.76 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL355955 | 0.76 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL31386549 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1CYP1A2THRB | |
| SCHEMBL381230 | 0.76 | TDP1 (0.44) | ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL9751561 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | TFPI, TFPI2, SPINT2 | ALDH1A1 2646/4885KMT2A 3337/4885MEN1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.